 SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 GLOBE NEWSWIRE -- Assembly Biosciences, Inc. Nasdaq: ASMB, a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus HBV, today announced it has selected a fourth core inhibitor candidate, ABI-4334 4334, that has been optimized for potency, to advance into clinical development. The company is conducting preclinical work, with the aim of completing regulatory filings and initiating clinical studies as soon as possible in 2022. 